Approval ProbabilityThe probability of approval for VTP-300 has been reduced from 45% to 15%.
Financial PerformanceNet loss was $19.6M, or ($0.49) per share, more than the estimated loss of $12.0M due to foreign exchange, asset depreciation and workforce reduction.
Regulatory RisksRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.